Ultragenyx Pharmaceutical | RARE - Current Liabilities


Ultragenyx Pharmaceutical reported $340.02M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Immunic USD 30.08M 2.77M Sep/2025
Insmed USD 468.87M 51.66M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Kyowa Hakko Kirin JPY 181.08B 4.08B Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Moderna USD 1.99B 306M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xoma USD 28.3M 6.81M Sep/2025